Biktarvy Generic Cost 2026: What Patients Actually Pay

If you’ve looked up the price of Biktarvy without help, the number is alarming: $4,216 per month at the US list price. But that number is not what most patients actually pay. Depending on your insurance status, income, and state of residence, your real monthly cost could be anywhere from $4,216 down to $0 — and most patients end up at the lower end of that range.

This page explains every cost scenario for Biktarvy in 2026 — what insured patients pay, what Medicare and Medicaid patients pay, what uninsured patients pay, and what the licensed generic versions manufactured abroad cost. For details on HIV treatment options more broadly, see our overview.

The US List Price Explained

The wholesale acquisition cost (WAC) for Biktarvy as of January 2026 is $4,216 per month — or approximately $50,600 per year. This is the price Gilead Sciences charges wholesalers and distributors, and it is the number that appears on most drug pricing databases.

However, WAC is not the price patients pay at the pharmacy. In the US drug pricing system, the actual amount a patient pays depends on their insurance coverage, their plan’s negotiated rates, their deductible and copay structure, and whether they are enrolled in any assistance programs. For many patients, the actual out-of-pocket cost is dramatically lower than the list price.

What Patients Actually Pay — By Insurance Status

Gilead Advancing Access Copay Card

Gilead’s Advancing Access copay assistance program is available to commercially insured patients in the United States who have a valid Biktarvy prescription. Under this program, Gilead covers copay costs up to the program maximum, meaning most eligible patients pay $0 per month.

Who qualifies

• Must have commercial (private) health insurance — employer-sponsored, marketplace, or individual plans all qualify
• Must have a valid US prescription for Biktarvy
• Must be a US resident
• Government insurance (Medicare, Medicaid, TRICARE, VA) is not eligible for the copay card

How to enroll

Call Gilead’s Advancing Access program at 1-800-226-2056 or enroll online at GileadAdvancingAccess.com. Enrollment is quick — most patients can activate the card before their next refill.

Gilead Patient Assistance Program (PAP)

For uninsured or underinsured patients who do not qualify for the copay card, Gilead’s Patient Assistance Program (PAP) provides Biktarvy at no cost. This is a separate program from the copay card and serves patients without commercial insurance.

Eligibility requirements

• US resident with a valid Social Security number
• Valid Biktarvy prescription from a licensed US physician
• No prescription drug coverage (or inadequate coverage)
• Income eligibility — generally up to 500% of the Federal Poverty Level, though the exact threshold may vary

How to apply

Call Gilead Advancing Access at 1-800-226-2056 (Monday–Friday, 9 AM–8 PM ET). Your HIV care provider or case manager can also submit the application on your behalf, which is often faster.

ADAP and Ryan White HIV/AIDS Program

Medicare and Medicaid Coverage

Medicare Part D

Biktarvy is covered under Medicare Part D (prescription drug coverage), though plan-specific costs vary. As a brand-name specialty drug, Biktarvy is typically placed on a high-cost tier, which historically meant significant out-of-pocket costs for Medicare patients.

Since January 2024, the Inflation Reduction Act’s $2,000 annual out-of-pocket cap applies to all Medicare Part D enrollees. This means Medicare patients will pay no more than $2,000 per year for all covered drugs combined, providing meaningful protection for high-cost medications like Biktarvy.

Note that Gilead’s copay card cannot be used with Medicare. However, Extra Help (Low Income Subsidy) is available to qualifying Medicare patients and can substantially reduce costs further.

Medicaid

Most state Medicaid programs cover Biktarvy as it is a preferred antiretroviral in DHHS guidelines. Copays under Medicaid are typically minimal (often $1–$3 per prescription). Some states require prior authorization, which your HIV provider can handle on your behalf. Coverage terms and any prior authorization requirements vary by state — confirm with your state Medicaid program or HIV care team.

Why There Is No US Generic Biktarvy

The question patients ask most often is: why isn’t there a cheaper generic version? The answer is patents.

Gilead Sciences holds multiple patents covering Biktarvy — on the active ingredients, formulation, and manufacturing processes. Under US law, generic manufacturers cannot produce or sell a generic version of a drug while valid patents are in force. According to DrugPatentWatch’s 2026 analysis, the last relevant Biktarvy patents do not expire until November 8, 2036.

This means:

• No FDA-approved generic Biktarvy can legally be sold in the US before 2036 unless Gilead reaches a licensing agreement with a generic manufacturer
• Any product sold as “generic Biktarvy” inside the US before that date would be either unapproved, counterfeit, or illegally imported
• The 10-year wait is why patient assistance programs — not generics — are the primary cost-reduction pathway for US patients right now

Licensed Generic Cost Outside the US

Gilead Sciences has entered into voluntary licensing agreements with generic manufacturers in India, allowing them to produce and sell generic versions of Biktarvy in certain lower- and middle-income countries. These are not counterfeit products — they are manufactured under license and meet quality standards set by the licensing agreement.

The cost of India-manufactured licensed generic Biktarvy is approximately $95–$165 per bottle (30 tablets, one month supply) depending on the manufacturer and supplier.

However, these products are manufactured and sold for distribution in specific countries under the licensing terms. They are not FDA-approved and are not legally importable into the United States for personal use without individual authorization. For patients outside the US or in countries where these generics are legally available, they represent a significant cost reduction compared to the US brand price.

For a full guide to prices, manufacturers, and how patients in eligible countries access these products, see our detailed page on Biktarvy price in India.

Full Biktarvy Cost Comparison Table (2026)

Common Mistakes Patients Make with Biktarvy Cost

Paying full price without checking for assistance programs

The single most common and costly mistake. A significant number of patients — particularly newly diagnosed or newly insured — pay high out-of-pocket costs for months before discovering the copay card or PAP exists. Check program eligibility before your first fill, not after several expensive refills.

Assuming Medicare patients can’t get help

Medicare patients cannot use the Gilead copay card, but they are not without options. Extra Help (Low Income Subsidy), ADAP, and Ryan White can all provide additional cost relief for Medicare beneficiaries. Many patients eligible for Extra Help are not enrolled — ask your pharmacist or HIV case manager to check your eligibility.

Not re-enrolling the copay card after a plan change

The copay card needs to be re-verified when your insurance changes — including annual open enrollment plan switches. If you changed plans at the start of the year and are now paying more at the pharmacy, the copay card may simply need to be re-processed with your new insurance information. Call 1-800-226-2056.

Stopping treatment due to cost without exploring options first

This is the most clinically dangerous mistake. Stopping Biktarvy abruptly — particularly for patients co-infected with hepatitis B — can have serious medical consequences. If cost is a barrier, contact your HIV clinic, a case manager, or Gilead directly before missing a dose. Programs exist specifically to prevent treatment interruption due to cost.

Purchasing from unverified online sources claiming to sell US generic Biktarvy

No legal US generic exists. Any website offering generic Biktarvy for delivery within the United States is selling either an unapproved product, a counterfeit, or a product obtained through unregulated channels. The health and legal risks of this route are significant. Use only the verified assistance programs described above.

Frequently Asked Questions

Final Thoughts

The $4,216 list price for Biktarvy is a real number, but it is not the number most patients need to worry about. The US HIV treatment infrastructure — imperfect as it is — has built multiple overlapping safety nets that bring the cost to $0 for the majority of patients who need them. The problem is not that these programs don’t exist. The problem is that patients don’t always know about them.

If you are newly diagnosed, newly losing insurance, or have seen your pharmacy costs spike unexpectedly, the first call to make is to Gilead’s Advancing Access program at 1-800-226-2056. If you don’t qualify for the copay card, they can help navigate you toward PAP, ADAP, or Ryan White. Your HIV clinic’s social worker or patient navigator can also do this on your behalf.

No patient should be rationing or stopping Biktarvy due to cost without exhausting these options first. For the full picture on what Biktarvy is and how it works, see our complete Biktarvy generic guide. For patients outside the US exploring licensed generic options, see our guide to Biktarvy price in India.